Black Diamond Therapeutics Inc

NASDAQ:BDTXUnited States

Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company is focused on the discovery and development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. Its technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. The Company’s lead product candidate, BDTX-1535 is a brain-penetrant inhibitor that targets a spectrum of epidermal growth factor receptor (EGFR) mutations, including allosteric and canonical mutations. Its second product candidate, BDTX-4933, is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic B-Raf Proto-Oncogene (BRAF) Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations, such as rat sarcoma virus (RAS) mutations, which has the potential to avoid paradoxical activation.

Contact Information

Headquarters

One Main Street, 14Th FloorCAMBRIDGE, MA, United States 02142

Phone

617-417-5868

Fax

---

Executives

Chairman of the Board

Mark Velleca

President, Chief Executive Officer, Director

David Epstein

Executive Vice President - Discovery and Translational Sciences

Elizabeth Buck

Chief Financial Officer, Chief Business Officer

Fang Ni

Chief Operating Officer, General Counsel

Brent Hatzis-Schoch